besides, if nanopore is that good, Illumina wouldn't have easily given up there stake. a piece of junk, hahaha.
hahaha, nanopore has never shown any kind of data except for some "squiggles" on a computer screen. I'm glad to see the nanopore drama is unfolding faster. without surprise, I would predict they will announce the delay of the so called Early access program for "technical reason" later this month.
Our SMRT technology has the potential to impact scientific study beyond DNA sequencing. We, and our scientific collaborators, have published a number of peer-reviewed articles in journals including Science, Nature and Nature; Methods highlighting the power and potential applications of the SMRT platform. Potential commercial applications we have demonstrated include the study of chemical and structural modifications of DNA and the processing of RNA and; proteins. Our research and development efforts are focused on expanding our DNA sequencing capabilities and commercializing products based on these research findings. We believe that our SMRT platform represents a new paradigm in biological science, which we refer to as SMRT Biology, that has the potential to significantly impact a number of areas critical to humankind, including the diagnosis and treatment of disease as well as efforts to improve the world’s food and energy supply.
Our mission is to transform the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research.
We have developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. Combining recent advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, we created a powerful technology platform called single molecule, real-time, or SMRT, technology. SMRT technology enables real-time analysis of biomolecules with single molecule resolution, which has the potential to transform our understanding of biological systems by providing a window into these systems that has not previously been open for scientific study.
Our initial focus is on the DNA sequencing market where we have developed and introduced a novel sequencing platform, the PacBio RS II. We believe that the PacBio RS II, which uses our proprietary SMRT technology, maintains many of the key attributes of currently available sequencing technologies while solving many of the inherent limitations of previous technologies. Our system provides long readlengths, flexibility in experimental design, fast time to result and significant ease of use. The PacBio RS II consists of an instrument platform that uses our consumables including our proprietary SMRT Cell. The system is designed to be integrated into existing laboratory workflows and information systems, which should facilitate rapid adoption. Currently, our focus is on applications for clinical, basic and agricultural research, with potential uses in molecular diagnostics, drug discovery and development, food safety, forensics, biosecurity and biofuels.
ok, once you get there, you need to click on EVENTS & PRESENTATION tab on the left, then you will find the webcast. good luck,
google "Pacific Biosciences of California Management Discusses Q3 2013 Results - Earnings Call Transcript" you will find it in seeking alpha. you need to register with them to read the whole article though. registration is free.
A single-molecule long-read survey of the human transcriptome.
Global RNA studies have become central to understanding biological processes, but methods such as microarrays and short-read sequencing are unable to describe an entire RNA molecule from 5' to 3' end. Here we use single-molecule long-read sequencing technology from Pacific Biosciences to sequence the polyadenylated RNA complement of a pooled set of 20 human organs and tissues without the need for fragmentation or amplification. We show that full-length RNA molecules of up to 1.5 kb can readily be monitored with little sequence loss at the 5' ends. For longer RNA molecules more 5' nucleotides are missing, but complete intron structures are often preserved. In total, we identify ∼14,000 spliced GENCODE genes. High-confidence mappings are consistent with GENCODE annotations, but 10% of the alignments represent intron structures that were not previously annotated. As a group, transcripts mapping to unannotated regions have features of long, noncoding RNAs. Our results show the feasibility of deep sequencing full-length RNA from complex eukaryotic transcriptomes on a single-molecule level.
A complete genome sequence is an extremely valuable tool in many types of scientific research, yet most organisms do not have their complete genome assembled — including humans. Instead, complex genomes are partially completed with difficult repetitive sections and longer structural variants excluded from the assembly, resulting in highly fragmented, incomplete genomes. To sequence the complete genome of an organism, very long sequencing reads are required to span these regions, which can be critical in understanding gene function. The very long sequence reads provided by the PacBio RS II Single Molecule, Real-time (SMRT®) sequencing system provide researchers the opportunity to fill gaps or reduce the number of fragments in assemblies of moderate and large genomes.
"We are delighted to have Roche as our in vitro diagnostics partner," stated Mike Hunkapiller, President and Chief Executive Officer of Pacific Biosciences. "As a world leader in in vitro diagnostics, Roche brings valuable expertise in designing products for clinical use and obtaining regulatory approvals to sell clinical products in the U.S. and around the world. We believe the combination of our SMRT Sequencing technology with Roche's market position and expertise in diagnostics will allow accelerated commercial success for both companies."
Commenting on the agreement, Dan Zabrowski, Head of the Sequencing Unit at Roche said, "We see great potential in Pacific Biosciences' sequencing technology for the development of future clinical sequencing applications. Sequencing will be a key technology in addressing the strong and growing demand for genetic and genomic solutions in the clinic. We are looking forward to this partnership to accelerate and support the transition of DNA sequencing into routine diagnostics through our joint development efforts."
Kevin Corcoran from PacBio announces new chemistry available soon with many read lengths longer than 20 kb, and lots of exciting applications demonstrated by pacbio users.